Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $43.00 at Truist Financial

Keros Therapeutics (NASDAQ:KROS) had its price objective reduced by Truist Financial from $100.00 to $43.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also recently commented on KROS. Wedbush reiterated an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Wells Fargo & Company increased their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Oppenheimer lowered their price target on shares of Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, December 16th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. Finally, William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $17.12 on Monday. Keros Therapeutics has a fifty-two week low of $15.67 and a fifty-two week high of $73.00. The stock has a market cap of $693.48 million, a P/E ratio of -3.29 and a beta of 1.20. The firm’s fifty day moving average price is $54.97 and its 200-day moving average price is $51.62.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same period in the prior year, the business posted ($1.33) earnings per share. The firm’s revenue was up 4750.0% on a year-over-year basis. On average, analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after purchasing an additional 18,755 shares in the last quarter. Rhumbline Advisers increased its position in shares of Keros Therapeutics by 20.6% during the second quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock valued at $1,903,000 after buying an additional 7,111 shares during the period. Arizona State Retirement System raised its stake in Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after buying an additional 1,130 shares in the last quarter. Quest Partners LLC lifted its holdings in Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after buying an additional 4,789 shares during the period. Finally, American Century Companies Inc. boosted its position in Keros Therapeutics by 24.9% during the 2nd quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock valued at $13,626,000 after acquiring an additional 59,364 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.